5 completed, 5 recruiting, 1 active not recruiting, 1 withdrawn. 6 Phase 2, 4 Phase 1, 1 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 4, Active not recruiting 1, Recruiting 1 |
| Phase 1 | 4 | Recruiting 3, Active not recruiting 1 |
| Not applicable | 1 | Recruiting 1 |
| Phase 3 | 1 | Withdrawn 1 |
Follow Thymidine: new trials by email Literature Review of Thymidine trials Research Report on Thymidine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pancreas Lipotoxicity in T2D: Edinburgh Diabetes Remission Study (EDRS) Total Diet Replacement (TDR) Program - Type 2 Diabetes | Not applicable | Recruiting | University of Edinburgh | 104 | 2026-06-15 | 2026-06-18 |
| Nucleoside Therapy in Patients With Telomere Biology Disorders deoxycytidine, deoxythymidine - Telomere Biology Disorders, Dyskeratosis Congenita | Phase 1 | Recruiting | Suneet Agarwal | 36 | 2025-09-29 | 2026-08-04 |
| Beta-blocker Administration for Cardiomyocyte Division N-thymidine, Urine Collection, Echocardiogram - Tetralogy of Fallot, Double Outlet Right Ventricle | Phase 1 | Recruiting | Weill Medical College of Cornell University | 40 | 2022-12-16 | 2026-10-26 |
| A Study of the Efficacy and Safety of MT1621 in Thymidine Kinase 2 (TK2) Deficiency (Treatment naïve) MT1621 - Thymidine Kinase 2 Deficiency | Phase 3 | Withdrawn | Zogenix MDS, Inc. | 2022-09-30 | 2023-09-01 | |
| Deoxynucleosides Pyrimidines as Treatment for Mitochondrial Depletion Syndrome deoxycytidine and deoxythymidine - Mitochondrial Diseases, Mitochondrial Encephalomyopathy | Phase 2 | Recruiting | Kenneth Myers, MD | 200 | 2021-10-18 | 2026-10-19 |
| Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer Trifluridine and Tipiracil Hydrochloride, Talazoparib Tosylate - Advanced Malignant Solid Neoplasm, Clinical Stage III Gastroesophageal Junction Adenocarcinoma | Phase 1 | Recruiting | Roswell Park Cancer Institute | 45 | 2021-06-08 | 2026-05-04 |
| TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study Irinotecan, Bevacizumab, Trifluridine and Tipiracil Hydrochloride - Advanced Colorectal Carcinoma, Metastatic Colon Adenocarcinoma | Phase 2 | Completed | Roswell Park Cancer Institute | 42 | 2019-12-27 | 2026-02-10 |
| Use of Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy for the Treatment of Resectable Esophageal or Gastroesophageal Junction (GEJ) Adenocarcinoma Trifluridine and Tipiracil Hydrochloride, Oxaliplatin - Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8 | Phase 2 | Completed | Roswell Park Cancer Institute | 22 | 2019-12-20 | 2025-04-29 |
| An Open-Label Study of Continuation Treatment With Combination Pyrimidine Nucleosides in Patients With TK2 Deficiency doxecitine and doxribtimine - Thymidine Kinase 2 Deficiency | Phase 2 | Completed | UCB BIOSCIENCES, Inc. | 47 | 2019-07-05 | 2026-09-08 |
| A RETROspective Study of Patients With TK2d dC/dT - Thymidine Kinase 2 (TK2) | Completed | Zogenix MDS, Inc. | 38 | 2018-11-19 | 2023-09-01 | |
| Treatment of TK2 Deficiency With Thymidine and Deoxycytidine Thymidine - Mitochondrial DNA Depletion Syndrome 2 Myopathic Type, Thymidine Kinase 2 Deficiency | Phase 1 / Phase 2 | Active not recruiting | Columbia University | 23 | 2017-05-16 | 2026-01-28 |
| Phase II Study of Ribose, Uridine, and Thymidine for a Complex Syndrome Involving Excessive 5'-Nucleotidase Activity ribose, thymidine, uridine - 5'-Nucleotidase Syndrome | Phase 2 | Completed | National Center for Research Resources (NCRR) | 1995-03-01 | 2005-06-24 |
Mitochondrial Diseases (3) · Muscle Weakness (3) · Colorectal Neoplasms (2) · Muscular Atrophy (2) · 5-Nucleotidase syndrome (1) · Blepharoptosis (1) · Bone Marrow Failure Disorders (1) · Colonic Neoplasms (1) · Deglutition Disorders (1) · Diabetes Mellitus, Type 2 (1) · Double Outlet Right Ventricle (1) · Dyskeratosis Congenita (1) · Hoyeraal Hreidarsson syndrome (1) · Metabolism, Inborn Errors (1) · Mitochondrial Encephalomyopathies (1)
Roswell Park Cancer Institute (3) · Zogenix MDS, Inc. (2) · Columbia University (1) · Kenneth Myers, MD (1) · National Center for Research Resources (NCRR) (1) · Suneet Agarwal (1) · UCB BIOSCIENCES, Inc. (1) · University of Edinburgh (1) · Weill Medical College of Cornell University (1)
United States (8) · Israel (2) · Spain (2) · Canada (1) · United Kingdom (1)
Christos Fountzilas, MD (2) · Ahmad Al-Mrabeh, PhD (1) · Alice L. Yu (1) · Bernhard Kuhn, MD (1) · Christos Fountilas, MD (1) · Helen Reed, MD, MPH (1) · Kenneth Alexis MD Myers, MD PhD FRCPC (1) · Michio Hirano, MD (1)
PMID 33246973, PMID 11182283, PMID 12013896, PMID 12508073, PMID 12771225, PMID 12826641, PMID 15090651, PMID 15684706, PMID 16621917, PMID 16971696, PMID 16971699, PMID 17080429, PMID 17353390, PMID 17483096, PMID 17486094, PMID 17549623, PMID 18238797, PMID 18467430, PMID 18546365, PMID 19103785, PMID 19125351, PMID 19138848, PMID 19192035, PMID 19667227, PMID 19766516, PMID 19889013, PMID 20301762, PMID 20301791, PMID 20329599, PMID 20444604, PMID 21483760, PMID 21774628, PMID 21855607, PMID 22084276, PMID 22176657, PMID 22608879, PMID 22711161, PMID 23168274, PMID 23169334, PMID 23230576, PMID 23385875, PMID 23714749, PMID 23817075, PMID 23932787, PMID 245993, PMID 24708634, PMID 24968719, PMID 24985751, PMID 25857492, PMID 26342080
2018 (1), 2023 (1), R01HL155597 (1), R37CA282430 (1)